Skip to main content

Advertisement

Table 1 Baseline characteristics of all enrolled patients with locally advanced breast cancer

From: Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial

Characteristic FEC arm [cases (%)] PE arm [cases (%)] P value
Total 151 142  
Age (years) 0.430
 ≤35 5 (3.31) 8 (5.63)  
 >35 146 (96.69) 134 (94.37)  
Menopausal status 0.263
 Premenopausal 31 (20.53) 22 (15.49)  
 Postmenopausal 120 (79.47) 120 (84.51)  
Clinical tumor stage 0.075
 T2 106 (70.20) 86 (60.56)  
 T3 43 (28.48) 52 (36.62)  
 T4 2 (1.32) 4 (2.82)  
Clinical nodal status 0.497
 Involved 130 (86.09) 126 (88.73)  
 Not involved 21 (13.91) 16 (11.27)  
ER/PR status 0.533
 Positive 96 (63.58) 89 (62.68)  
 Negative 47 (31.13) 52 (36.62)  
 Missing 8 (5.30) 1 (0.70)  
HER2 (IHC staining) 0.189
 0/1+ 64 (42.38) 66 (46.48)  
 2+ 31 (20.53) 26 (18.31)  
 3+ 45 (29.80) 47 (33.10)  
Missing 11 (7.28) 3 (2.11)  
  1. PE weekly paclitaxel–epirubicin regimen, FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, ER estrogen receptor, PR progesterone receptor, HER2 epidermal growth factor receptor-2, IHC immunohistochemistry